Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
Authors:
- H M GolombHGH M Golomb
- J W VardimanJVJ W Vardiman
- C A WestbrookCWC A Westbrook
- C BarkerCBC Barker
- A HoobermanAHA Hooberman
- M A BitterMBM A Bitter
- K DalyKDK Daly
- 1 November 1988
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 6 (11) , 1714-1721
Abstract
Sixty-nine patients with hairy-cell leukemia (HCL) were treated with interferon alfa-2b (IFN) in a single-institution study. The dose used was 2 x 10(6) U/m2 self-administered subcutaneously three times weekly, for a planned treatment duration of 12 to 18 months. Of the 68 evaluable patients, the major response rate was 75%, with 13% complete responses (CRs) and 62% partial responses (PRs). An additional eleven patients (16%) had minor responses (MRs). Duration of response was denoted as failure-free survival (FFS), defined as the time from the end of IFN therapy to a need for further antileukemic therapy. Of the 60 responding patients followed after discontinuation of IFN, 27 have relapsed, requiring further therapy. The median actuarial FFS for these 60 patients is 25.4 months. All but five patients are alive, and the actuarial overall survival for the 69 patients is 91% +/- 4% at 4 years from the start of IFN. The best indicators of relapse were the neutrophil alkaline phosphatase (NAP) score and degree of residual bone marrow hairy cells (%HCL) at the completion of therapy. Patients with NAP less than 30 (n = 21) had the best prognosis (median FFS, 30.4 months), while those with NAP greater than or equal to 30 and %HCL less than or equal to 30 (n = 21) or %HCL greater than 30 (n = 16) had intermediate and poor prognoses, respectively (median FFS, 23.5 and 12.4 months) (P = .0005). Fourteen of the relapsing patients are evaluable for response to a second course of IFN, with seven PRs and four MRs. Stratified randomized trials are indicated to determine the role of maintenance therapy for responding patients.Keywords
This publication has 18 references indexed in Scilit:
- Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic resultsThe American Journal of Medicine, 1986
- Changes in Peripheral Blood and Bone Marrow Specimens Following Therapy with Recombinant Alpha2 Interferon for Hairy Cell LeukemiaAmerican Journal of Clinical Pathology, 1986
- Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha2-interferonHuman Pathology, 1985
- Interferon is effective in hairy‐cell leukaemiaBritish Journal of Haematology, 1985
- TREATMENT OF HAIRY-CELL LEUKEMIA WITH RECOMBINANT ALPHA-2 INTERFERON1985
- Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin).Journal of Clinical Oncology, 1984
- Alpha Interferon for Induction of Remission in Hairy-Cell LeukemiaNew England Journal of Medicine, 1984
- Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvementBlood, 1983
- Significance of Leukocyte Alkaline Phosphatase in Hairy Cell LeukemiaAmerican Journal of Clinical Pathology, 1980
- Leukemic ReticuloendotheliosisBlood, 1958